Legal status · United States
Is Semaglutide with cagrilintide legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Semaglutide with cagrilintide is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Semaglutide with cagrilintide in the United States at a glance
| Classification | Not approved; research use only |
|---|---|
| Note | Semaglutide is approved as a single agent. Cagrilintide is investigational, so a blend containing it is not a lawful medicine and is sold only by research chemical vendors. |
| FDA approval status | The co-formulated combination has been trialled at phase 3 and is the subject of regulatory filings. A research chemical blend sold under its description is not that product and is not approved. |
| Human studies cited | 4 of 4 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Semaglutide with cagrilintide profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
No product containing Semaglutide with cagrilintide is approved by FDA for any use in the United States, so nothing on the market is authorized for people.
- 02
"Research use only" is a vendor label, not a legal category that permits human use. It does not exempt a product from medicines law.
- 03
Importing, supplying or promoting it for human use can fall under medicines legislation in the United States. This page is general information, not legal advice.
What Semaglutide with cagrilintide is
The rare blend whose combination has actually been trialled, at scale: co-administered cagrilintide and semaglutide produced 20.4% mean weight loss at week 68 against 3.0% on placebo in 3,417 participants. What research vendors sell under this description is not that product, at that ratio, from that supply chain, and gastrointestinal adverse events affected 79.6% of the combination group in the trial.
This page has to do two jobs at once, and keeping them separate is the whole point. First job: the combination is real and it works.
Mechanism: Semaglutide agonises the GLP-1 receptor. Cagrilintide is a long-acting amylin analogue acting on satiety through amylin receptor signalling in the hindbrain.
Regulatory history: The co-formulated combination has been trialled at phase 3 and is the subject of regulatory filings. A research chemical blend sold under its description is not that product and is not approved.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Semaglutide with cagrilintide at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Semaglutide with cagrilintide in other countries
Frequently asked questions
Is Semaglutide with cagrilintide legal in the United States?
No. Semaglutide with cagrilintide is not an approved medicine in the United States; its classification is "Not approved; research use only". Nothing containing it is authorized for any use in people. Vials labeled "for research use only" are not exempt: that label does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: Semaglutide is approved as a single agent. Cagrilintide is investigational, so a blend containing it is not a lawful medicine and is sold only by research chemical vendors.
Can I buy Semaglutide with cagrilintide in the United States?
No approved product exists to buy. In the United States Semaglutide with cagrilintide is classified as "Not approved; research use only", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Semaglutide is approved as a single agent. Cagrilintide is investigational, so a blend containing it is not a lawful medicine and is sold only by research chemical vendors.
Is Semaglutide with cagrilintide FDA approved?
No. FDA status: The co-formulated combination has been trialled at phase 3 and is the subject of regulatory filings. A research chemical blend sold under its description is not that product and is not approved.. Current US classification: "Not approved; research use only". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Semaglutide with cagrilintide live on its compound profile.
Semaglutide with cagrilintide profileThis page is general information about the regulatory status of Semaglutide with cagrilintide in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.